Aelis Farma SA (AELIS.PA)
EUR 2.18
(2.83%)
EUR 2.18
(2.83%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -16.19 Million EUR | 47.04% |
| 2022 | -30.57 Million EUR | -67.06% |
| 2021 | -18.3 Million EUR | -1261.23% |
| 2020 | 1.57 Million EUR | 240.21% |
| 2019 | -1.12 Million EUR | 44.9% |
| 2018 | -2.04 Million EUR | 12.6% |
| 2017 | -2.33 Million EUR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | -8.66 Million EUR | 13.42% |
| 2024 Q1 | -8.66 Million EUR | 46.49% |
| 2023 Q3 | -16.3 Million EUR | 22.9% |
| 2023 FY | -16.19 Million EUR | 47.04% |
| 2023 Q4 | -16.19 Million EUR | 0.69% |
| 2023 Q2 | -21.14 Million EUR | 0.47% |
| 2023 Q1 | -21.24 Million EUR | 30.51% |
| 2022 Q4 | -30.57 Million EUR | 0.03% |
| 2022 Q3 | -30.58 Million EUR | 17.7% |
| 2022 Q2 | -37.15 Million EUR | -4.54% |
| 2022 Q1 | -35.54 Million EUR | -94.21% |
| 2022 FY | -30.57 Million EUR | -67.06% |
| 2021 FY | -18.3 Million EUR | -1261.23% |
| 2021 Q2 | -23.18 Million EUR | -0.86% |
| 2021 Q3 | -16.81 Million EUR | 27.48% |
| 2021 Q4 | -18.3 Million EUR | -8.84% |
| 2021 Q1 | -22.98 Million EUR | -1558.63% |
| 2020 Q1 | 5.77 Million EUR | 0.0% |
| 2020 Q4 | 1.57 Million EUR | -11.16% |
| 2020 Q3 | 1.77 Million EUR | 0.0% |
| 2020 FY | 1.57 Million EUR | 240.21% |
| 2019 FY | -1.12 Million EUR | 44.9% |
| 2018 FY | -2.04 Million EUR | 12.6% |
| 2017 FY | -2.33 Million EUR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| ABIONYX Pharma SA | -714 Thousand EUR | -2167.787% |
| ABIVAX Société Anonyme | -196.47 Million EUR | 91.759% |
| Adocia SA | 127 Thousand EUR | 12849.606% |
| Biophytis S.A. | 2.7 Million EUR | 699.038% |
| Advicenne S.A. | 12.17 Million EUR | 232.994% |
| genOway Société anonyme | 2.97 Million EUR | 644.641% |
| IntegraGen SA | -709.74 Thousand EUR | -2181.37% |
| Medesis Pharma S.A. | 1.15 Million EUR | 1498.019% |
| Neovacs S.A. | -237.08 Thousand EUR | -6729.56% |
| NFL Biosciences SA | -2.27 Million EUR | -611.464% |
| Plant Advanced Technologies SA | 4.35 Million EUR | 471.674% |
| Quantum Genomics Société Anonyme | -830.54 Thousand EUR | -1849.556% |
| Sensorion SA | 1.37 Million EUR | 1274.847% |
| Theranexus Société Anonyme | 2.44 Million EUR | 762.478% |
| TME Pharma N.V. | -1.07 Million EUR | -1400.649% |
| Valbiotis SA | -18.13 Million EUR | 10.734% |
| TheraVet SA | 12.78 Thousand EUR | 126748.416% |
| Valerio Therapeutics Société anonyme | 2.18 Million EUR | 842.752% |
| argenx SE | -1.83 Billion EUR | 99.118% |
| BioSenic S.A. | 28.04 Million EUR | 157.738% |
| Celyad Oncology SA | -6.1 Million EUR | -165.356% |
| DBV Technologies S.A. | -114.95 Million USD | 85.915% |
| Galapagos NV | -157.2 Million EUR | 89.7% |
| Genfit S.A. | -7.61 Million EUR | -112.745% |
| GeNeuro SA | 5.91 Million EUR | 373.958% |
| Hyloris Pharmaceuticals SA | -25.11 Million EUR | 35.521% |
| Innate Pharma S.A. | -30.71 Million EUR | 47.278% |
| Inventiva S.A. | 10.48 Million EUR | 254.371% |
| MaaT Pharma SA | -10.2 Million EUR | -58.667% |
| MedinCell S.A. | 39.5 Million EUR | 140.991% |
| Nanobiotix S.A. | -24.71 Million EUR | 34.493% |
| Onward Medical N.V. | -12.89 Million EUR | -25.578% |
| Oryzon Genomics S.A. | 1.43 Million EUR | 1232.043% |
| OSE Immunotherapeutics SA | 27.12 Million EUR | 159.685% |
| Oxurion NV | 10.71 Million EUR | 251.186% |
| Pharming Group N.V. | 99.4 Million EUR | 116.289% |
| Poxel S.A. | 44.55 Million EUR | 136.338% |
| GenSight Biologics S.A. | 16.29 Million EUR | 199.374% |
| Transgene SA | -14.4 Million EUR | -12.374% |
| Financière de Tubize SA | 78.62 Million EUR | 120.594% |
| UCB SA | 2.17 Billion EUR | 100.744% |
| Valneva SE | 82.73 Million EUR | 119.571% |
| Vivoryon Therapeutics N.V. | -18.52 Million EUR | 12.589% |